Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinsons Disease
Enrolling By Invitation
30-80 years
All
640 participants needed
1 Location
Brief description of study
The LRRK2protein may contribute to disease progression in patients with PD.The study drug (BIIB122) is designed to affect the activity of LRRK2 protein in the brain and may prevent or delay the development of PD symptoms.The main purpose of this study is to look at whether the study drug works in people with early-stage PD, how safe it is in terms of medical problems known as side effects, and how the body handles taking it (tolerability).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Parkinsons
-
Age: Between 30 Years - 80 Years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 851898
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
